What Gelofusin Treats: Main Uses and Benefits

Gelofusin is a plasma volume substitute used primarily to replace fluid lost from the circulation. Its therapeutic domain focuses on addressing the effects of relative or absolute low blood volume (hypovolaemia) and conditions associated with shock.

It is commonly administered to patients who require volume replacement following significant fluid and blood loss due to severe trauma, a surgical procedure, or extensive burns. The medicine is also indicated for the prevention of low blood pressure (hypotension) and can be used as a component of the priming fluid during procedures like the use of a heart-lung machine.

The essential patient benefit is the stabilisation of circulation, which supports the maintenance of blood flow and oxygen supply to vital organs, contributing to the management of related symptoms.

Quick Fact: Relief for Symptoms of Low Blood Volume

Gelofusin's population eligibility is strictly defined by regulatory contraindications and restrictions, primarily centered on volume status and allergic risk. The medicine must not be administered to patients with hypervolaemia (excess blood volume), overhydration, or acute congestive cardiac failure. Absolute contraindications also include known hypersensitivity to gelatin or Alpha-Gal syndrome (allergy to red meat/offal) due to the severe risk of anaphylactic reaction. The following groups require conditional use or are not fully established:

• Paediatric Population: Use in children is not completely established due to insufficient experience and is restricted to cases where the expected benefits clearly outweigh potential risks.
• Organ Impairment: Patients with severe renal insufficiency or those prone to circulatory overload (e.g., cardiac insufficiency, hypertension) must receive the medicine with special caution and close monitoring.
• Pregnancy: Use is generally avoided but may be given in emergency situations if clinically imperative; use during lactation is permitted as excretion into breast milk is not expected to be in relevant amounts.

Interactions with other medicines and products

Official regulatory documents state that classical pharmacological interactions (such as metabolic or transporter-mediated effects) are not known for Gelofusin. The documented interaction profile centers on pharmacodynamic risks related to fluid balance and procedural constraints.

Documented Interactions and Constraints

Timing and Procedural Rules

To prevent the colloid from interfering with diagnostic results, blood samples required for laboratory tests are recommended to be drawn before the infusion of Gelofusin. The interaction profile does not contain any mandatory timing separation rules for other medicines, nor does it list specific interactions with food, alcohol, or herbal products.

Gelofusin (succinylated gelatin solution) functions as a plasma volume expander. The mechanism involves the introduction of succinylated gelatin macromolecules into the intravascular compartment. These macromolecules increase the plasma oncotic pressure (pipl) within the capillaries. This resulting osmotic gradient induces the movement of water from the interstitial space into the intravascular compartment. The subsequent shift in fluid leads to a rapid increase in circulating volume, which in turn causes an increase in cardiac output and mean arterial pressure. The duration of the volume effect is determined by the elimination kinetics. The gelatin is partially cleared by renal excretion, with the remaining fraction metabolized by plasma proteases.

Gelofusin is administered as an Intravenous Infusion using a standard drip or a pressure infusion set in a controlled clinical setting, such as a hospital or emergency unit. The dosage volume and rate are highly variable and are adjusted based on the patient's continuously monitored circulatory status and the amount of fluid lost.

Dosing and Administration Rules

Gelofusin is administered on an as-needed basis; the frequency is determined by ongoing assessments of the patient’s volume deficit, not a fixed schedule. The effect of a single infusion typically lasts for approximately 3 to 4 hours. Use in the paediatric population requires caution and especially careful monitoring due to limited clinical experience, and the therapy is reserved for when the benefit clearly outweighs potential risks.

Research Evidence / Overview of Studies for Gelofusin

Gelofusin (Succinylated Gelatin) was studied in research exploring its role as a plasma volume substitute. The research base primarily consists of short-term Randomized Controlled Trials (RCTs) and various Systematic Reviews and Meta-analyses. Studies often included other intravenous fluids as comparators, such as saline (crystalloids) and other colloid solutions (like albumin).

Evidence for Volume Replacement in Acute Hypovolaemia and Shock

This section summarizes the types of controlled trials and systematic reviews that have investigated Gelofusin's role in contexts of severe fluid loss.

Researchers conducted studies to explore the solution's properties in patients experiencing a drop in blood volume due to causes like major surgery or acute trauma. Studies primarily focused on haemodynamic endpoints, such as tracking a patient's blood pressure and cardiac output to examine how these measures evolved after administration. Findings described patterns observed in the measurement of plasma volume expansion. Other research also monitored clinical resource utilization, such as the total volume of fluid needed and the requirement for allogeneic blood products (transfusions).

However, the certainty remains low in some areas. Trial heterogeneity—the inclusion of diverse patient populations (for example, surgical, trauma, and septic patients) within the same analyses—can limit the ability to draw consistent conclusions for any single group. The evidence from many existing studies provides limited insight into differences in organ function endpoints, such as long-term renal outcomes, when compared to crystalloids.

Evidence for Preventing Low Blood Pressure During Anaesthesia

This part covers the specific clinical trials that have explored the use of Gelofusin as a fluid administered before certain types of regional anaesthesia.

Studies reported measurements of the frequency of low blood pressure episodes (hypotension) in groups receiving the gelatin solution compared to those who received other fluid types. Trial outcomes also documented the total dose of supporting medications needed to maintain blood pressure targets during the operative period. However, findings were mixed in systematic reviews regarding the degree of difference between gelatin solutions and crystalloid solutions.

Uncertainty exists because existing studies often focus on a narrow, specific surgical context, which limits the generalizability of the findings to all types of regional anaesthesia. Comparative evidence is lacking regarding the optimal technique.

Research on Long-Term Outcomes and Durability

Because Gelofusin was studied for acute, short-term situations like surgery or emergency resuscitation, most research has focused on immediate or short-term outcomes (usually ≤24 to 48 hours). For major patient-centered outcomes, such as overall survival, evidence is based on large Systematic Reviews and Meta-analyses that sometimes track results up to 90 days.

Long-term effects are not fully established. Follow-up durations were limited, meaning the durability of the change in fluid volume and any patient outcomes beyond the intermediate 90-day tracking period are not well characterized across the overall body of evidence.

Studies in Specific Patient Groups (Special Populations)

The core research base largely consists of data from adult populations. While some trials have included specific populations like pregnant individuals, data for certain groups remain insufficient. Research that has explored outcomes in pediatric patients (infants and children) remains limited. Certainty remains low for specific young age groups.

Uncertainty and Research Gaps

The existing body of research, while providing context, still contains important research gaps. Key limitations include small sample sizes in some RCTs, meaning the statistical power to detect meaningful differences in major outcomes is modest. Research does not determine whether an individual will respond similarly to the patients studied. The overall data show patterns related to how studies examined plasma volume, but the comparative evidence is lacking in certain specific subgroups of critically ill patients. The research highlights what is known—and what is still uncertain regarding long-term outcomes and consistency across all clinical contexts.

Common questions about Gelofusin (FAQ)

Q: What is Gelofusin and what is it used for?

A: Gelofusin is a plasma volume substitute that contains succinylated gelatin. It is used to temporarily increase blood volume when a person has lost a significant amount of blood or plasma, such as during surgery or trauma.

Q: How is Gelofusin administered?

A: Gelofusin is administered by a healthcare professional directly into a vein, typically through an intravenous (IV) infusion. The rate and amount of the infusion are determined by the treating physician based on the patient's specific clinical needs.

Q: Are there known side effects associated with Gelofusin?

A: As with any medication, some individuals may experience side effects. Reported effects may include hypersensitivity reactions (allergic reactions), which can range from mild skin rashes to more severe, though uncommon, reactions like anaphylaxis. The healthcare team closely monitors the patient during administration.

Official Storage and Disposal Requirements

Regulatory agencies mandate that Gelofusin solution must be stored below 25 C. It is essential to not refrigerate or freeze the container, as this is strictly prohibited to maintain product stability. Users should also ensure the product is kept out of the reach and sight of children.

Handling and Stability Rules

Gelofusin is intended for immediate use upon opening, and therefore has no defined shelf-life after first use. If the solution is noticed to be cloudy, discolored, or if the container is leaking, it must not be used. Any solution that is previously opened or partially used must be discarded.

Disposal Instructions

Unused medicine or waste material must be disposed of in accordance with local requirements and should not be disposed of via household waste or wastewater. Consulting a pharmacist for proper disposal methods helps ensure environmental protection.